{"id":260305,"date":"2017-05-29T07:01:00","date_gmt":"2017-05-29T05:01:00","guid":{"rendered":"http:\/\/hudo.com\/si\/2017\/05\/29\/dobra-priloznost-za-vlagatelje\/"},"modified":"2017-05-29T07:01:00","modified_gmt":"2017-05-29T05:01:00","slug":"dobra-priloznost-za-vlagatelje","status":"publish","type":"post","link":"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/","title":{"rendered":"Dobra prilo\u017enost za vlagatelje"},"content":{"rendered":"<p>Kategorija: Finance Mon, 29 May 2017 09:01:00 +0200  Celgene Corporation (CELG US) je eno izmed najve\u010djih biofarmacevtskih podjetij na svetu, ki se osredoto\u010da na razvoj zdravil za zdravljenje rakavih obolenj in vnetij. Razvili so zdravilo za zdravljenje raka kostnega mozga (MDS) in bolezni krvotvornih mati\u010dnih celic. Poleg tega se ukvarjajo tudi z razvojem zdravil za zdravljenje levkemije, raka na prsih, raka celic limfati\u010dnega tkiva in razli\u010dnih vnetij. Podjetje je bilo ustanovljeno leta 1986 v ameri\u0161ki zvezni dr\u017eavi New Jersey in se vse od ustanovitve ukvarja z biotehnologijo, ki v nasprotju s klasi\u010dnimi farmacevtskimi podjetij razvoj zdravil sloni na preu\u010devanju celic in genov. Iz start-up podjetja so v treh desetletjih postali eno izmed najve\u010djih globalnih biofarmacevtskih podjetij. Rast na ra\u010dun raziskav in razvoja Najbolj prodajano zdravilo, ki pomeni skoraj 2\/3 prihodkov, je Revlimind, za zdravljenje raka kostnega mozga in bolezni\u00a0&#8230;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kategorija: Finance Mon, 29 May 2017 09:01:00 +0200  Celgene Corporation (CELG US) je eno izmed najve\u010djih biofarmacevtskih podjetij na svetu, ki se osredoto\u010da na razvoj zdravil za zdravljenje rakavih obolenj in vnetij. Razvili so zdravilo za zdravljenje raka kostnega mozga (MDS) in bolezni krvotvornih mati\u010dnih celic. Poleg tega se ukvarjajo tudi z razvojem zdravil za zdravljenje levkemije, raka na prsih, raka celic limfati\u010dnega tkiva in razli\u010dnih vnetij. Podjetje je bilo ustanovljeno leta 1986 v ameri\u0161ki zvezni dr\u017eavi New Jersey in se vse od ustanovitve ukvarja z biotehnologijo, ki v nasprotju s klasi\u010dnimi farmacevtskimi podjetij razvoj zdravil sloni na preu\u010devanju celic in genov. Iz start-up podjetja so v treh desetletjih postali eno izmed najve\u010djih globalnih biofarmacevtskih podjetij. Rast na ra\u010dun raziskav in razvoja Najbolj prodajano zdravilo, ki pomeni skoraj 2\/3 prihodkov, je Revlimind, za zdravljenje raka kostnega mozga in bolezni\u00a0&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1179],"tags":[],"source":[1703],"supertag":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Dobra prilo\u017enost za vlagatelje - Hudo Slovenija<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/\" \/>\n<meta property=\"og:locale\" content=\"sl_SI\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dobra prilo\u017enost za vlagatelje - Hudo Slovenija\" \/>\n<meta property=\"og:description\" content=\"Kategorija: Finance Mon, 29 May 2017 09:01:00 +0200 Celgene Corporation (CELG US) je eno izmed najve\u010djih biofarmacevtskih podjetij na svetu, ki se osredoto\u010da na razvoj zdravil za zdravljenje rakavih obolenj in vnetij. Razvili so zdravilo za zdravljenje raka kostnega mozga (MDS) in bolezni krvotvornih mati\u010dnih celic. Poleg tega se ukvarjajo tudi z razvojem zdravil za zdravljenje levkemije, raka na prsih, raka celic limfati\u010dnega tkiva in razli\u010dnih vnetij. Podjetje je bilo ustanovljeno leta 1986 v ameri\u0161ki zvezni dr\u017eavi New Jersey in se vse od ustanovitve ukvarja z biotehnologijo, ki v nasprotju s klasi\u010dnimi farmacevtskimi podjetij razvoj zdravil sloni na preu\u010devanju celic in genov. Iz start-up podjetja so v treh desetletjih postali eno izmed najve\u010djih globalnih biofarmacevtskih podjetij. Rast na ra\u010dun raziskav in razvoja Najbolj prodajano zdravilo, ki pomeni skoraj 2\/3 prihodkov, je Revlimind, za zdravljenje raka kostnega mozga in bolezni\u00a0...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/\" \/>\n<meta property=\"og:site_name\" content=\"Hudo Slovenija\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/hudo.si\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-29T05:01:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hudo.com\/si\/wp-content\/uploads\/sites\/2\/2017\/05\/480x290_0526__DelnicaCelgene.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"480\" \/>\n\t<meta property=\"og:image:height\" content=\"290\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"hudo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hudo_si\" \/>\n<meta name=\"twitter:site\" content=\"@hudo_si\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hudo\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuta\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/\"},\"author\":{\"name\":\"hudo\",\"@id\":\"https:\/\/hudo.com\/si\/#\/schema\/person\/601cf3379633985b20f7e50f2bb47707\"},\"headline\":\"Dobra prilo\u017enost za vlagatelje\",\"datePublished\":\"2017-05-29T05:01:00+00:00\",\"dateModified\":\"2017-05-29T05:01:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/\"},\"wordCount\":149,\"publisher\":{\"@id\":\"https:\/\/hudo.com\/si\/#organization\"},\"articleSection\":[\"Aktualno\"],\"inLanguage\":\"sl-SI\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/\",\"url\":\"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/\",\"name\":\"Dobra prilo\u017enost za vlagatelje - Hudo Slovenija\",\"isPartOf\":{\"@id\":\"https:\/\/hudo.com\/si\/#website\"},\"datePublished\":\"2017-05-29T05:01:00+00:00\",\"dateModified\":\"2017-05-29T05:01:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/#breadcrumb\"},\"inLanguage\":\"sl-SI\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hudo.com\/si\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dobra prilo\u017enost za vlagatelje\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hudo.com\/si\/#website\",\"url\":\"https:\/\/hudo.com\/si\/\",\"name\":\"Hudo Slovenija\",\"description\":\"Vse novice iz Slovenije in sveta\",\"publisher\":{\"@id\":\"https:\/\/hudo.com\/si\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hudo.com\/si\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"sl-SI\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/hudo.com\/si\/#organization\",\"name\":\"VSN Media\",\"url\":\"https:\/\/hudo.com\/si\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sl-SI\",\"@id\":\"https:\/\/hudo.com\/si\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/hudo.com\/si\/wp-content\/uploads\/sites\/2\/2021\/03\/hudo-app-2.png\",\"contentUrl\":\"https:\/\/hudo.com\/si\/wp-content\/uploads\/sites\/2\/2021\/03\/hudo-app-2.png\",\"width\":2185,\"height\":2167,\"caption\":\"VSN Media\"},\"image\":{\"@id\":\"https:\/\/hudo.com\/si\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/hudo.si\",\"https:\/\/twitter.com\/hudo_si\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/hudo.com\/si\/#\/schema\/person\/601cf3379633985b20f7e50f2bb47707\",\"name\":\"hudo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sl-SI\",\"@id\":\"https:\/\/hudo.com\/si\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c4ca25fa72cace7a696b52ff5db9e095?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c4ca25fa72cace7a696b52ff5db9e095?s=96&d=mm&r=g\",\"caption\":\"hudo\"},\"url\":\"https:\/\/hudo.com\/si\/author\/hudo\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dobra prilo\u017enost za vlagatelje - Hudo Slovenija","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/","og_locale":"sl_SI","og_type":"article","og_title":"Dobra prilo\u017enost za vlagatelje - Hudo Slovenija","og_description":"Kategorija: Finance Mon, 29 May 2017 09:01:00 +0200 Celgene Corporation (CELG US) je eno izmed najve\u010djih biofarmacevtskih podjetij na svetu, ki se osredoto\u010da na razvoj zdravil za zdravljenje rakavih obolenj in vnetij. Razvili so zdravilo za zdravljenje raka kostnega mozga (MDS) in bolezni krvotvornih mati\u010dnih celic. Poleg tega se ukvarjajo tudi z razvojem zdravil za zdravljenje levkemije, raka na prsih, raka celic limfati\u010dnega tkiva in razli\u010dnih vnetij. Podjetje je bilo ustanovljeno leta 1986 v ameri\u0161ki zvezni dr\u017eavi New Jersey in se vse od ustanovitve ukvarja z biotehnologijo, ki v nasprotju s klasi\u010dnimi farmacevtskimi podjetij razvoj zdravil sloni na preu\u010devanju celic in genov. Iz start-up podjetja so v treh desetletjih postali eno izmed najve\u010djih globalnih biofarmacevtskih podjetij. Rast na ra\u010dun raziskav in razvoja Najbolj prodajano zdravilo, ki pomeni skoraj 2\/3 prihodkov, je Revlimind, za zdravljenje raka kostnega mozga in bolezni\u00a0...","og_url":"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/","og_site_name":"Hudo Slovenija","article_publisher":"https:\/\/www.facebook.com\/hudo.si","article_published_time":"2017-05-29T05:01:00+00:00","og_image":[{"width":480,"height":290,"url":"https:\/\/hudo.com\/si\/wp-content\/uploads\/sites\/2\/2017\/05\/480x290_0526__DelnicaCelgene.jpeg","type":"image\/jpeg"}],"author":"hudo","twitter_card":"summary_large_image","twitter_creator":"@hudo_si","twitter_site":"@hudo_si","twitter_misc":{"Written by":"hudo","Est. reading time":"1 minuta"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/#article","isPartOf":{"@id":"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/"},"author":{"name":"hudo","@id":"https:\/\/hudo.com\/si\/#\/schema\/person\/601cf3379633985b20f7e50f2bb47707"},"headline":"Dobra prilo\u017enost za vlagatelje","datePublished":"2017-05-29T05:01:00+00:00","dateModified":"2017-05-29T05:01:00+00:00","mainEntityOfPage":{"@id":"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/"},"wordCount":149,"publisher":{"@id":"https:\/\/hudo.com\/si\/#organization"},"articleSection":["Aktualno"],"inLanguage":"sl-SI"},{"@type":"WebPage","@id":"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/","url":"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/","name":"Dobra prilo\u017enost za vlagatelje - Hudo Slovenija","isPartOf":{"@id":"https:\/\/hudo.com\/si\/#website"},"datePublished":"2017-05-29T05:01:00+00:00","dateModified":"2017-05-29T05:01:00+00:00","breadcrumb":{"@id":"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/#breadcrumb"},"inLanguage":"sl-SI","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/hudo.com\/si\/aktualno\/dobra-priloznost-za-vlagatelje\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hudo.com\/si\/"},{"@type":"ListItem","position":2,"name":"Dobra prilo\u017enost za vlagatelje"}]},{"@type":"WebSite","@id":"https:\/\/hudo.com\/si\/#website","url":"https:\/\/hudo.com\/si\/","name":"Hudo Slovenija","description":"Vse novice iz Slovenije in sveta","publisher":{"@id":"https:\/\/hudo.com\/si\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hudo.com\/si\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"sl-SI"},{"@type":"Organization","@id":"https:\/\/hudo.com\/si\/#organization","name":"VSN Media","url":"https:\/\/hudo.com\/si\/","logo":{"@type":"ImageObject","inLanguage":"sl-SI","@id":"https:\/\/hudo.com\/si\/#\/schema\/logo\/image\/","url":"https:\/\/hudo.com\/si\/wp-content\/uploads\/sites\/2\/2021\/03\/hudo-app-2.png","contentUrl":"https:\/\/hudo.com\/si\/wp-content\/uploads\/sites\/2\/2021\/03\/hudo-app-2.png","width":2185,"height":2167,"caption":"VSN Media"},"image":{"@id":"https:\/\/hudo.com\/si\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/hudo.si","https:\/\/twitter.com\/hudo_si"]},{"@type":"Person","@id":"https:\/\/hudo.com\/si\/#\/schema\/person\/601cf3379633985b20f7e50f2bb47707","name":"hudo","image":{"@type":"ImageObject","inLanguage":"sl-SI","@id":"https:\/\/hudo.com\/si\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c4ca25fa72cace7a696b52ff5db9e095?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c4ca25fa72cace7a696b52ff5db9e095?s=96&d=mm&r=g","caption":"hudo"},"url":"https:\/\/hudo.com\/si\/author\/hudo\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/hudo.com\/si\/wp-json\/wp\/v2\/posts\/260305"}],"collection":[{"href":"https:\/\/hudo.com\/si\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hudo.com\/si\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hudo.com\/si\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hudo.com\/si\/wp-json\/wp\/v2\/comments?post=260305"}],"version-history":[{"count":0,"href":"https:\/\/hudo.com\/si\/wp-json\/wp\/v2\/posts\/260305\/revisions"}],"wp:attachment":[{"href":"https:\/\/hudo.com\/si\/wp-json\/wp\/v2\/media?parent=260305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hudo.com\/si\/wp-json\/wp\/v2\/categories?post=260305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hudo.com\/si\/wp-json\/wp\/v2\/tags?post=260305"},{"taxonomy":"source","embeddable":true,"href":"https:\/\/hudo.com\/si\/wp-json\/wp\/v2\/source?post=260305"},{"taxonomy":"supertag","embeddable":true,"href":"https:\/\/hudo.com\/si\/wp-json\/wp\/v2\/supertag?post=260305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}